{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:08:47Z","timestamp":1792822127282,"version":"4.5.0"},"reference-count":171,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jaad.2018.03.055","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T20:54:56Z","timestamp":1523652896000},"page":"1179-1196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["Hair disorders in patients with cancer"],"prefix":"10.1016","volume":"80","author":[{"given":"Azael","family":"Freites-Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Nangia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Paus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.03.055_bib1","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jaad.2018.03.055_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pon.1245","article-title":"Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review","volume":"17","author":"Lemieux","year":"2008","journal-title":"Psychooncology"},{"key":"10.1016\/j.jaad.2018.03.055_bib3","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2011.02.026","article-title":"Chemotherapy-induced alopecia","volume":"67","author":"Chon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/jocd.12308","article-title":"Chemotherapy-induced alopecia management: clinical experience and practical advice","volume":"16","author":"Rossi","year":"2017","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0974-7753.77528","article-title":"Radiation-induced alopecia","volume":"2","author":"Ali","year":"2010","journal-title":"Int J Trichology"},{"key":"10.1016\/j.jaad.2018.03.055_bib6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/annonc\/mdv390","article-title":"Alopecia in patients treated with molecularly targeted anticancer therapies","volume":"26","author":"Belum","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune\u00a0checkpoint inhibitors","volume":"176","author":"Zarbo","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib8","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/bmt.2017.15","article-title":"Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood","volume":"52","author":"Bresters","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2018.03.055_bib9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","article-title":"Alopecia with endocrine therapies in patients with cancer","volume":"18","author":"Saggar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2018.03.055_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2165\/00002018-199410040-00005","article-title":"Drug-induced hair loss and hair growth","volume":"10","author":"Tosti","year":"1994","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2018.03.055_bib11","first-page":"139","article-title":"Changes in self-concept and body image during alopecia induced cancer chemotherapy","volume":"5","author":"M\u00fcnstedt","year":"1997","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib12","first-page":"1461","article-title":"Unanticipated toxicities from anticancer therapies: survivors' perspectives","volume":"18","author":"Gandhi","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib13","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1200\/JCO.2004.08.080","article-title":"Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study","volume":"22","author":"Bezjak","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib14","first-page":"267","article-title":"Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study","volume":"16","author":"Hackbarth","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/1097-0142(197003)25:3<715::AID-CNCR2820250332>3.0.CO;2-9","article-title":"Effect of large intermittent intravenous doses of cyclophosphamide in lymphoma","volume":"25","author":"Mendelson","year":"1970","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib16","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/1097-0142(196011\/12)13:6<1254::AID-CNCR2820130614>3.0.CO;2-U","article-title":"Clinical evaluation of a new alkylating agent: cytoxan (cyclophosphamide)","volume":"13","author":"Coggins","year":"1960","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0022-3476(62)80341-2","article-title":"Cyclophosphamide in the treatment of common neoplastic diseases of childhood","volume":"61","author":"Sweeney","year":"1962","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaad.2018.03.055_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF01806239","article-title":"Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer","volume":"3","author":"Brincker","year":"1983","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2018.03.055_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/thx.20.6.555","article-title":"Cyclophosphamide in the management of advanced bronchial carcinoma","volume":"20","author":"McLean","year":"1965","journal-title":"Thorax"},{"key":"10.1016\/j.jaad.2018.03.055_bib20","first-page":"2023","article-title":"A randomized clinical trial of daunorubicin and a combination of prednisone, vincristine, 6-mercaptopurine, and methotrexate in adult acute nonlymphocytic leukemia","volume":"32","author":"Wiernik","year":"1972","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2018.03.055_bib21","first-page":"921","article-title":"Daunorubicin in the therapy of acute granulocytic leukemia","volume":"33","author":"Weil","year":"1973","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2018.03.055_bib22","series-title":"Taxotere [package insert]","year":"2010"},{"key":"10.1016\/j.jaad.2018.03.055_bib23","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1200\/JCO.1995.13.10.2643","article-title":"Docetaxel","volume":"13","author":"Cortes","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib24","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0959-8049(99)00122-7","article-title":"Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group","volume":"35","author":"Sjostrom","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib25","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/sj.bjc.6600645","article-title":"Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure","volume":"87","author":"Bonneterre","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib27","first-page":"13","article-title":"Permanent alopecia in women being treated for breast cancer","volume":"13","author":"Masidonski","year":"2009","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.jaad.2018.03.055_bib28","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1989.7.5.560","article-title":"Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer","volume":"7","author":"Henderson","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0936-6555(05)80851-9","article-title":"A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma","volume":"5","author":"Lawton","year":"1993","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jaad.2018.03.055_bib30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00176978","article-title":"Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer","volume":"9","author":"Saxman","year":"1991","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2018.03.055_bib31","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/S0959-8049(97)00183-4","article-title":"Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group","volume":"33","author":"Sahmoud","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF00177478","article-title":"Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma","volume":"27","author":"Fulton","year":"1996","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib33","series-title":"Idarubicin [package insert]","year":"2006"},{"key":"10.1016\/j.jaad.2018.03.055_bib34","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A phase III trial comparing idarubicin and daunorubicin in combination with\u00a0cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study","volume":"10","author":"Vogler","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib35","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/1097-0142(19891215)64:12<2431::AID-CNCR2820641206>3.0.CO;2-1","article-title":"A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer","volume":"64","author":"Lopez","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib36","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/0959-8049(95)00212-2","article-title":"CPT-11 (irinotecan) in the treatment of colorectal cancer","volume":"31a","author":"Armand","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib37","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","article-title":"Phase II trial of irinotecan in patients with metastatic colorectal carcinoma","volume":"15","author":"Pitot","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib38","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0959-8049(99)00150-1","article-title":"CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer","volume":"35","author":"Andre","year":"1999","journal-title":"GERCOR Eur J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00280-006-0372-9","article-title":"Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer","volume":"60","author":"Duffour","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2018.03.055_bib40","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/annonc\/mdn680","article-title":"A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02\/FFCD9802)","volume":"20","author":"Ychou","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib41","doi-asserted-by":"crossref","first-page":"E442","DOI":"10.1002\/ijc.29115","article-title":"Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis","volume":"136","author":"Shin","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib42","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.1999.17.6.1876","article-title":"Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma","volume":"17","author":"Gill","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib43","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/jnci\/92.13.1074","article-title":"Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer","volume":"92","author":"Ranson","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jaad.2018.03.055_bib44","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2001.19.5.1275","article-title":"Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study","volume":"19","author":"Curtin","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/030089160409000304","article-title":"Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study","volume":"90","author":"Lombardi","year":"2004","journal-title":"Tumori"},{"key":"10.1016\/j.jaad.2018.03.055_bib46","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-006-9306-9","article-title":"Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer","volume":"101","author":"Gasparini","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2018.03.055_bib47","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib48","series-title":"Hycamtin [package insert]","year":"2014"},{"key":"10.1016\/j.jaad.2018.03.055_bib49","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib50","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.2005.03.6491","article-title":"Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer","volume":"24","author":"Ramlau","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib52","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0936-6555(03)00148-1","article-title":"Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features","volume":"15","author":"Gerrard","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jaad.2018.03.055_bib53","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/pbc.24554","article-title":"Acute toxicity of proton beam radiation for pediatric central nervous system malignancies","volume":"60","author":"Suneja","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib54","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/ped.12624","article-title":"Proton beam therapy for pediatric ependymoma","volume":"57","author":"Mizumoto","year":"2015","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jaad.2018.03.055_bib55","first-page":"217.e1-11","article-title":"Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy","volume":"71","author":"Reyes-Habito","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib56","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","article-title":"Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial","volume":"86","author":"Basset-Seguin","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib57","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects\u00a0in\u00a0patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib58","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/pbc.25429","article-title":"Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis","volume":"62","author":"Belum","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib60","first-page":"43","article-title":"Busulphan\/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth","volume":"7","author":"Baker","year":"1991","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jaad.2018.03.055_bib61","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1067\/mjd.2003.44","article-title":"Adverse cutaneous\u00a0reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients","volume":"48","author":"Valeyrie","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib62","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib63","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1658-3876(09)50026-X","article-title":"Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia","volume":"2","author":"Aleem","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jaad.2018.03.055_bib64","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2017.2106","article-title":"Hair repigmentation during immunotherapy treatment with an anti-programmed cell death 1 and anti-programmed cell death ligand 1 agent for lung cancer","volume":"153","author":"Rivera","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib65","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib66","first-page":"236","article-title":"The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors","volume":"4","author":"Lacouture","year":"2006","journal-title":"J Support Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib67","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/pgmj.64.757.907","article-title":"Hair changes following cytotoxic drug induced alopecia","volume":"64","author":"Fairlamb","year":"1988","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jaad.2018.03.055_bib68","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/j.jaad.2009.11.589","article-title":"Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib","volume":"63","author":"Vergou","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib70","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouche","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib71","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2004.06265.x","article-title":"Trichomegaly following treatment with gefitinib (ZD1839)","volume":"151","author":"Pascual","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.sder.2008.12.001","article-title":"Chemotherapy-induced alopecia","volume":"28","author":"Trueb","year":"2009","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2018.03.055_bib73","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1259\/bjr.73.871.11089467","article-title":"Absorbed dose and deterministic effects to patients from interventional neuroradiology","volume":"73","author":"Mooney","year":"2000","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jaad.2018.03.055_bib74","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood.V74.5.1507.1507","article-title":"Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia","volume":"74","author":"Beelen","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2018.03.055_bib75","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of chemotherapy-induced hair loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib76","first-page":"543","article-title":"Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches","volume":"12","author":"Hesketh","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000102031","article-title":"Hair loss pattern due to chemotherapy-induced anagen effluvium: a cross-sectional observation","volume":"215","author":"Yun","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.03.055_bib78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/MO:23:1:57","article-title":"Epiphora (excessive tearing) and other ocular manifestations related to weekly docetaxel: underestimated dose-limiting toxicity","volume":"23","author":"Tsalic","year":"2006","journal-title":"Med Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib79","first-page":"347","article-title":"Factors affecting hair regrowth after bone marrow transplantation","volume":"12","author":"Vowels","year":"1993","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jaad.2018.03.055_bib80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1440-0960.2012.00946.x","article-title":"Exclamation marks and other trichoscopic signs of chemotherapy-induced alopecia","volume":"54","author":"Pirmez","year":"2013","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib81","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1468-3083.2012.04530.x","article-title":"Dermoscopy guided scalp biopsy in cicatricial\u00a0alopecia","volume":"27","author":"Miteva","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.03.055_bib82","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0303-8467(03)00007-6","article-title":"Radiation-induced temporary alopecia after embolization of cerebral arteriovenous malformations","volume":"105","author":"Wen","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jaad.2018.03.055_bib83","first-page":"8202469","article-title":"Radiation-induced alopecia after endovascular embolization under fluoroscopy","volume":"2016","author":"Ounsakul","year":"2016","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.jaad.2018.03.055_bib84","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13014-015-0547-9","article-title":"Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: a prospective analysis","volume":"10","author":"Cox","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib85","first-page":"5343","article-title":"Topical management of acute radiation dermatitis in breast cancer patients: a systematic review and meta-analysis","volume":"37","author":"Haruna","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jaad.2018.03.055_bib86","doi-asserted-by":"crossref","first-page":"415.e1-15","DOI":"10.1016\/j.jaad.2014.05.008","article-title":"Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination","volume":"71","author":"Mubki","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib87","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jaad.2012.06.041","article-title":"Dermatoscopy of hair shaft disorders","volume":"68","author":"Miteva","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib88","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1600-0560.2009.01275.x","article-title":"A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib","volume":"36","author":"Pongpudpunth","year":"2009","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2018.03.055_bib89","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jaad.2015.01.011","article-title":"RASopathic alopecia: hair changes associated with vemurafenib therapy","volume":"72","author":"Piraccini","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000475543","article-title":"Trichoscopic findings of erosive pustular dermatosis of the scalp associated with gefitinib","volume":"9","author":"Fukui","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib91","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2230.2008.02882.x","article-title":"Tufted hair folliculitis in a woman treated with lapatinib for breast cancer","volume":"33","author":"Ena","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib92","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","article-title":"Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2018.03.055_bib93","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3325\/cmj.2016.57.229","article-title":"High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease","volume":"57","author":"Ceovic","year":"2016","journal-title":"Croat Med J"},{"key":"10.1016\/j.jaad.2018.03.055_bib94","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamadermatol.2014.1550","article-title":"Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease","volume":"151","author":"Zuo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib95","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine therapy-induced alopecia in patients with breast cancer","volume":"154","author":"Freites-Martinez","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib96","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1200\/JCO.2011.39.3611","article-title":"Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor study","volume":"30","author":"Kinahan","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib97","doi-asserted-by":"crossref","first-page":"mdx655.022","DOI":"10.1093\/annonc\/mdx655.022","article-title":"Incidence of permanent chemotherapy-induced alopecia among breast cancer patients: a five-year prospective cohort study","volume":"28","author":"Kang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib98","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2009.26.4432","article-title":"Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib","volume":"28","author":"Sideras","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib99","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.03.055_bib100","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/1346-8138.12654","article-title":"Reversible hair depigmentation in a Japanese female treated with pazopanib","volume":"41","author":"Kobayashi","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib101","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archderm.144.11.1525","article-title":"Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition","volume":"144","author":"Hartmann","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib102","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1056\/NEJMicm1309906","article-title":"Images in clinical medicine. Sunitinib-associated hair depigmentation","volume":"370","author":"Brzezniak","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.03.055_bib103","first-page":"92","article-title":"A single-arm phase II Austrian\/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)","volume":"16","author":"Hutterer","year":"2014","journal-title":"Neurooncology"},{"key":"10.1016\/j.jaad.2018.03.055_bib104","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1684\/ejd.2014.2462","article-title":"Eruptive nevi and hair depigmentation related to regorafenib","volume":"25","author":"Sibaud","year":"2015","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib105","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1200\/JCO.2011.34.6858","article-title":"Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer","volume":"29","author":"Rodriguez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib106","first-page":"4","article-title":"Persistent hair growth during treatment with the EGFR inhibitor erlotinib","volume":"15","author":"Alexandrescu","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2018.03.055_bib107","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01243894-200611000-00020","article-title":"Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer","volume":"1","author":"Carser","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib108","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1056\/NEJMicm073144","article-title":"Images in clinical medicine. Erlotinib-induced hair alterations","volume":"358","author":"Gerber","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.03.055_bib109","first-page":"1656","article-title":"Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody","volume":"142","author":"Kerob","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib110","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1200\/JCO.2005.01.9570","article-title":"Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab","volume":"23","author":"Montagut","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib111","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamadermatol.2017.0500","article-title":"Severe onycholysis and eyelash trichomegaly following use of new selective pan-FGFR inhibitors","volume":"153","author":"Betrian","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib112","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/0284186X.2010.509107","article-title":"Toxicity manifesting as cosmetic hair alterations during erlotinib treatment","volume":"50","author":"Kudo","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib113","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jid.2015.10.068","article-title":"Modeling chemotherapy-induced hair loss: from experimental propositions toward clinical reality","volume":"136","author":"Botchkarev","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib114","first-page":"5002","article-title":"p53 is essential for chemotherapy-induced hair loss","volume":"60","author":"Botchkarev","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2018.03.055_bib115","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/JID.2015.358","article-title":"Development of a model for chemotherapy-induced alopecia: profiling of histological changes in human hair follicles after chemotherapy","volume":"136","author":"Yoon","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib116","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1046\/j.1523-1747.1998.00417.x","article-title":"Do hair bulb melanocytes undergo apoptosis during hair follicle regression (catagen)?","volume":"111","author":"Tobin","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib117","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0167-8140(97)00059-5","article-title":"Response of human hair cortical cells to fractionated radiotherapy","volume":"43","author":"Hamilton","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib118","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.0022-202X.2004.22344.x","article-title":"Estrogens and human scalp hair growth-still more questions than answers","volume":"122","author":"Conrad","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib119","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1087-0024.2005.10115.x","article-title":"Substantial sex-dependent differences in the response of human scalp\u00a0hair follicles to estrogen stimulation in\u00a0vitro advocate\u00a0gender-tailored management of female versus male pattern balding","volume":"10","author":"Conrad","year":"2005","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2018.03.055_bib120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1210\/er.2006-0020","article-title":"The hair follicle as an estrogen target and source","volume":"27","author":"Ohnemus","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jaad.2018.03.055_bib121","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bmj.314.7079.481","article-title":"Alopecia and breast disease","volume":"314","author":"Gateley","year":"1997","journal-title":"BMJ Clin Res Ed"},{"key":"10.1016\/j.jaad.2018.03.055_bib122","doi-asserted-by":"crossref","first-page":"743","DOI":"10.5021\/ad.2014.26.6.743","article-title":"Pattern alopecia during hormonal anticancer therapy in patients with breast cancer","volume":"26","author":"Park","year":"2014","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib123","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1534735404270335","article-title":"Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness","volume":"3","author":"Conklin","year":"2004","journal-title":"Integr Cancer Ther"},{"key":"10.1016\/j.jaad.2018.03.055_bib124","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/exd.13347","article-title":"The biology and genetics of curly hair","volume":"26","author":"Westgate","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/exd.13337","article-title":"The hair follicle enigma","volume":"26","author":"Bernard","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib126","series-title":"World Health Organization Handbook for Reporting Results of Cancer Treatment","first-page":"48","author":"World Health Organization","year":"1979"},{"key":"10.1016\/j.jaad.2018.03.055_bib127","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJM197912273012605","article-title":"Prevention of doxorubicin-induced hair loss with scalp hypothermia","volume":"301","author":"Dean","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.03.055_bib128","author":"Comis"},{"key":"10.1016\/j.jaad.2018.03.055_bib129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1097-0215(19960103)65:1<97::AID-IJC17>3.0.CO;2-F","article-title":"The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models","volume":"65","author":"Sredni","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib131","first-page":"509","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib132","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed July 29, 2018."},{"key":"10.1016\/j.jaad.2018.03.055_bib133","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0002-9378(81)90746-8","article-title":"Hirsutism: implications, etiology, and management","volume":"140","author":"Hatch","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jaad.2018.03.055_bib134","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological sequelae and alopecia among women with cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract"},{"key":"10.1016\/j.jaad.2018.03.055_bib135","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pon.3531","article-title":"Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients","volume":"23","author":"Choi","year":"2014","journal-title":"Psychooncology"},{"key":"10.1016\/j.jaad.2018.03.055_bib136","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00002820-199408000-00006","article-title":"Social and cultural dimensions of hair loss in women treated for breast cancer","volume":"17","author":"Freedman","year":"1994","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.jaad.2018.03.055_bib137","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1471-6712.1992.tb00128.x","article-title":"Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer","volume":"6","author":"Tierney","year":"1992","journal-title":"Scand J Caring Sci"},{"key":"10.1016\/j.jaad.2018.03.055_bib138","first-page":"483","article-title":"Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy","volume":"26","author":"Smith","year":"2018","journal-title":"Support Care Cancer"},{"issue":"suppl 3","key":"10.1016\/j.jaad.2018.03.055_bib139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2133.2011.10632.x","article-title":"An overview of unwanted female hair","volume":"165","author":"Blume-Peytavi","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib140","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1056\/NEJMcp033496","article-title":"Clinical practice","volume":"353","author":"Rosenfield","year":"2005","journal-title":"Hirsutism N Engl J Med"},{"key":"10.1016\/j.jaad.2018.03.055_bib141","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting and clinical site inspections","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2018.03.055_bib142","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdt476","article-title":"Development and validation of Chemotherapy-induced Alopecia Distress Scale (CADS) for breast cancer patients","volume":"25","author":"Cho","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib143","doi-asserted-by":"crossref","first-page":"A458","DOI":"10.1016\/S1098-3015(10)75269-4","article-title":"Validation and assessment of measurement invariance of the eyelash satisfaction questionnaire (ESQ) in US cancer patients [abstract]","volume":"12","author":"Dang","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jaad.2018.03.055_bib144","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/asj\/sjv154","article-title":"Development and validation of the Eyelash Satisfaction Questionnaire","volume":"36","author":"Dang","year":"2016","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.jaad.2018.03.055_bib145","first-page":"129","article-title":"The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies","volume":"12","author":"Granai","year":"1991","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib146","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0190-9622(96)90500-9","article-title":"A randomized trial of minoxidil in chemotherapy-induced alopecia","volume":"35","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib147","doi-asserted-by":"crossref","first-page":"e14064","DOI":"10.1200\/JCO.2017.35.15_suppl.e14064","article-title":"A phase I safety study of topical calcitriol (BPM 31543) for the prevention of chemotherapy-induced alopecia (CIA)","volume":"35","author":"Lacouture","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib148","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/jdv.14612","article-title":"Scalp\u00a0hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials","volume":"32","author":"Shah","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2018.03.055_bib149","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1054\/ejon.2000.0094","article-title":"Evaluating the efficacy of scalp cooling using the Penguin cold cap system to reduce alopecia in patients undergoing chemotherapy for breast cancer","volume":"4","author":"Peck","year":"2000","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.jaad.2018.03.055_bib150","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0959-8049(00)00012-5","article-title":"Prevention of chemotherapy-induced alopecia using an effective scalp cooling system","volume":"36","author":"Katsimbri","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib151","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2016.21038","article-title":"Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer","volume":"317","author":"Rugo","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2018.03.055_bib152","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.2016.20939","article-title":"Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial","volume":"317","author":"Nangia","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2018.03.055_bib153","first-page":"108","article-title":"Prevention of alopecia by scalp cooling of patients receiving adriamycin","volume":"57","author":"Luce","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.jaad.2018.03.055_bib154","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1088\/0967-3334\/28\/8\/006","article-title":"The relationship between local scalp skin temperature and cutaneous perfusion during scalp cooling","volume":"28","author":"Janssen","year":"2007","journal-title":"Physiol Meas"},{"key":"10.1016\/j.jaad.2018.03.055_bib155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0022-3565(24)37613-X","article-title":"Handling of doxorubicin by the LLC-PK1 kidney epithelial cell line","volume":"286","author":"Decorti","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2018.03.055_bib156","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/00365518509155250","article-title":"Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man","volume":"45","author":"Bulow","year":"1985","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.jaad.2018.03.055_bib157","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.2017.35.15_suppl.525","article-title":"COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer [abstract]","volume":"35","author":"Smetanay","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib158","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(00)04293-8","article-title":"Scalp cooling therapy and cytotoxic treatment","volume":"357","author":"Forsberg","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.03.055_bib159","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10549-017-4185-9","article-title":"Scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis","volume":"163","author":"Rugo","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2018.03.055_bib160","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1111\/ijd.13526","article-title":"Comments\u00a0regarding \u201cHair regrowth during chemotherapy after scalp cooling technique\u201d","volume":"56","author":"de Barros Silva","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib161","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10549-016-3799-7","article-title":"Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia","volume":"157","author":"Belum","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2018.03.055_bib162","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2015.09.003","article-title":"No prevention of radiotherapy-induced alopecia by scalp cooling","volume":"117","author":"van den Hurk","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jaad.2018.03.055_bib163","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-018-4996-3","article-title":"Safety of 5alpha-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies","volume":"174","author":"Rozner","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2018.03.055_bib164","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1038\/jidsymp.2013.30","article-title":"Safety and efficacy of bimatoprost solution\u00a00.03% topical application in patients with chemotherapy-induced eyelash loss","volume":"16","author":"Ahluwalia","year":"2013","journal-title":"J Invest Dermatol Symp Proc"},{"key":"10.1016\/j.jaad.2018.03.055_bib165","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.293.20.2516","article-title":"Personal use of hair dyes and risk of cancer: a meta-analysis","volume":"293","author":"Takkouche","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2018.03.055_bib166","first-page":"CD010334","article-title":"Interventions for hirsutism (excluding laser and photoepilation therapy alone)","volume":"4","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.03.055_bib167","first-page":"CD004684","article-title":"Laser and photoepilation for unwanted hair growth","volume":"4","author":"Haedersdal","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2018.03.055_bib168","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2018.03.055_bib169","first-page":"123","article-title":"Cellium\u00ae GC: evaluation of a new natural active ingredient in 210 mg\/ml topical solution, through scalp biopsy","volume":"3","author":"Cuc\u00e9","year":"2011","journal-title":"Surg Cosmet Dermatol"},{"key":"10.1016\/j.jaad.2018.03.055_bib170","author":"ClinicalTrials.gov website"},{"key":"10.1016\/j.jaad.2018.03.055_bib171","first-page":"273","article-title":"Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies","volume":"2","author":"Cuscela","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.jaad.2018.03.055_bib172","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-04-0658","article-title":"A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy","volume":"10","author":"Metz","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218305292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218305292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:50:28Z","timestamp":1759272628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218305292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":171,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0190962218305292"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.055","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hair disorders in patients with cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(19)30479-7","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}